Intellia Therapeutics (NTLA) Misses Q1 EPS by 3c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Intellia Therapeutics (NTLA) Misses Q1 EPS by 3c, Revenues Miss

Intellia Therapeutics Announces First Quarter 2021 Financial Results

May 6, 2021 7:30 AM EDT

Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND or IND-equivalent in mid-2021 to advance NTLA-5001 for acute myeloid leukemia (AML) Expect to submit an IND or IND-equivalent in 2H 2021 for NTLA-2002 for hereditary angioedema (HAE)Ended the quarter with a strong cash position of $600.8 million

CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) --... More